Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the CAR-HEMATOTOX model, which aids in determining whether a patient receiving CAR T-cell therapy is at risk of developing immune effector cell-associated hematotoxicity (ICAHT). The five components of this model include absolute neutrophil count (ANC), hemoglobin levels, platelet count, and two indicators of baseline inflammation – C-reactive protein (CRP) and ferritin. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.